Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism

J Clin Psychopharmacol. 2014 Oct;34(5):645-8. doi: 10.1097/JCP.0000000000000165.

Abstract

Current evidence suggests that polymorphism in the serotonin transporter gene (5-HTTLPR) predicts antidepressant efficacy in whites but less so in Asians. However, it is not clear whether this effect can be observed for specific types of antidepressant drugs. White (n = 47) and Korean (n = 118) participants with major depressive disorder were treated with escitalopram and assessed over 8 weeks. Among those with the l/l but not l/s or s/s genotypes, whites had greater depression score reductions, response rates, and remission rates compared with Koreans. Our results suggest that 5-HTTLPR predicts escitalopram efficacy in an ethnicity-dependent manner.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use
  • Asian People / genetics*
  • Asian People / psychology
  • Citalopram / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic / genetics
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Single-Blind Method
  • White People / genetics*
  • White People / psychology

Substances

  • Antidepressive Agents
  • Serotonin Plasma Membrane Transport Proteins
  • Citalopram